Mega Lifesciences Public Company Limited (MEGA-R) - Total Liabilities
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has total liabilities worth ฿4.37 Billion THB (≈ $136.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mega Lifesciences Public Company Limited - Total Liabilities Trend (2010–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's total liabilities have evolved over time, based on quarterly financial data. See MEGA-R current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Mega Lifesciences Public Company Limited Competitors by Total Liabilities
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Empire State Realty Trust Inc
NYSE:ESRT
|
USA | $2.31 Billion |
|
Warom Technology Inc Co
SHG:603855
|
China | CN¥2.72 Billion |
|
YD More Investments Ltd
TA:MRIN
|
Israel | ILA831.34 Million |
|
MAHLE Metal Leve S.A
SA:LEVE3
|
Brazil | R$2.93 Billion |
|
BeiJing Certificate Authority Co Ltd
SHE:300579
|
China | CN¥664.14 Million |
|
Shandong Xinhua Pharmaceutical Co Ltd
SHE:000756
|
China | CN¥3.87 Billion |
|
Nova Technology
TWO:6613
|
Taiwan | NT$4.64 Billion |
|
New Pacific Metals Corp
TO:NUAG
|
Canada | CA$1.06 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Mega Lifesciences Public Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mega Lifesciences Public Company Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mega Lifesciences Public Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mega Lifesciences Public Company Limited (2010–2024)
The table below shows the annual total liabilities of Mega Lifesciences Public Company Limited from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ฿4.33 Billion ≈ $135.07 Million |
-16.94% |
| 2023-12-31 | ฿5.22 Billion ≈ $162.62 Million |
-11.12% |
| 2022-12-31 | ฿5.87 Billion ≈ $182.95 Million |
+11.88% |
| 2021-12-31 | ฿5.25 Billion ≈ $163.53 Million |
+13.79% |
| 2020-12-31 | ฿4.61 Billion ≈ $143.71 Million |
+5.81% |
| 2019-12-31 | ฿4.36 Billion ≈ $135.82 Million |
+11.50% |
| 2018-12-31 | ฿3.91 Billion ≈ $121.82 Million |
+12.45% |
| 2017-12-31 | ฿3.48 Billion ≈ $108.33 Million |
+6.57% |
| 2016-12-31 | ฿3.26 Billion ≈ $101.65 Million |
-0.51% |
| 2015-12-31 | ฿3.28 Billion ≈ $102.17 Million |
+19.45% |
| 2014-12-31 | ฿2.74 Billion ≈ $85.53 Million |
-3.49% |
| 2013-12-31 | ฿2.84 Billion ≈ $88.62 Million |
+13.32% |
| 2012-12-31 | ฿2.51 Billion ≈ $78.20 Million |
+27.26% |
| 2011-12-31 | ฿1.97 Billion ≈ $61.45 Million |
+43.82% |
| 2010-12-31 | ฿1.37 Billion ≈ $42.73 Million |
-- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more